Murray Stahl’s Lantern Pharma LTRN Stock Holding History

Murray Stahl’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Sell	25,164 -1,209	-5%	-$3.54K	﹤0.01%	322
2026 Q1	$36.1K	Sell	26,373 -1,209	-4%	-$3.38K	﹤0.01%	340
2025 Q4	$83.6K	Sell	27,582 -1,209	-4%	-$4.5K	﹤0.01%	317
2025 Q3	$125K	Buy	28,791 +1,209	+4%	+$5.05K	﹤0.01%	319
2025 Q2	$87.2K	Sell	27,582 -1,209	-4%	-$4.08K	﹤0.01%	338
2025 Q1	$102K	Hold	28,791	–	–	﹤0.01%	329
2024 Q4	$91.8K	Buy	28,791 +1,209	+4%	+$4.14K	﹤0.01%	333
2024 Q3	$101K	Sell	27,582 -1,209	-4%	-$4.98K	﹤0.01%	329
2024 Q2	$134K	Hold	28,791	–	–	﹤0.01%	299
2024 Q1	$253K	Hold	28,791	–	–	﹤0.01%	267
2023 Q4	$123K	Sell	28,791 -1,209	-4%	-$4.26K	﹤0.01%	299
2023 Q3	$102K	Hold	30,000	–	–	﹤0.01%	312
2023 Q2	$169K	Hold	30,000	–	–	﹤0.01%	300
2023 Q1	$145K	Buy	+30,000	New	+$158K	﹤0.01%	304

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Murray Stahl's LTRN Position: Q2 2026 in Review

Murray Stahl reduced its Lantern Pharma (LTRN) stake by 4.6% in Q2 2026, selling an estimated $3.54K and leaving 25,164 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #322.

Murray Stahl first reported a position in LTRN in Q1 2023 and has held it in 14 quarters since. The position peaked at $253K in Q1 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Murray Stahl held 25,164 shares of Lantern Pharma worth $105K as of Q2 2026.
Murray Stahl sold 1,209 Lantern Pharma shares in Q2 2026, an estimated $3.54K.
Lantern Pharma made up ﹤0.01% of Murray Stahl's portfolio in Q2 2026, its #322 holding.
Murray Stahl first reported a position in Lantern Pharma in Q1 2023 and has held it in 14 quarters since.
Murray Stahl's Lantern Pharma position peaked at $253K in Q1 2024.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.